Few hospital-acquired infections are as antibiotic-resistant as Pseudomonas aeruginosa. This opportunistic germ has earned a reputation for beating nearly every drug in the doctor’s arsenal. It ...

Early ASH 2025 data suggest sonrotoclax is a promising therapy in MCL, supporting a broader shift toward chemo-free, combination-based strategies—particularly for patients with BTK ...

Findings from the international FORT-2 clinical trial showed that a combination treatment including immunotherapy is safe and tolerable in patients with locally advanced or metastatic bladder cancer.

Astellas Pharma Ltd. today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization for PADCEV ™ (enfortumab vedotin, an antibody-drug conjugate [ADC]) ...

University of Oregon researchers have tested a new combination drug therapy that could dismantle the difficult-to-treat bacteria inhabiting chronic wound infections. Their findings, published Sept. 29 ...

Four trials presented at the recent American Society of Clinical Oncology (ASCO) meeting showed promise of new drug combinations or monotherapies in treating chronic lymphocytic leukemia (CLL) and ...

A research team at the Medical University of Vienna has discovered a new approach to treating a particularly frequent and difficult-to-treat form of lung cancer. The study shows that a combination of ...

New research led by scientists at VCU Massey Comprehensive Cancer Center suggests that a class of drugs known as MCL-1 (myeloid leukemia cell-1) inhibitors interact with a type of kinase inhibitor ...